Cardiac Imaging

While cardiac ultrasound is the widely used imaging modality for heart assessments, computed tomography (CT), magnetic resonance imaging (MRI) and nuclear imaging are also used and are often complimentary, each offering specific details about the heart other modalities cannot. For this reason the clinical question being asked often determines the imaging test that will be used.

Societies must adapt to the rise of multimodality cardiac imaging
ASE President David Wiener detailed some of the many ways imaging societies need to adapt now that so many imagers are specializing in multiple modalities. It may be time to change how annual conferences are scheduled, for example, so that the costs of travel are easier to manage.
Women are more likely to have severe aortic stenosis missed on echocardiography results
Three out of four TTEs are being ordered by clinicians who are not cardiologists. Could this be having a negative impact on patient care?
New Medtronic thrombectomy system used commercially for first time
The new device uses an advanced algorithm to regulate aspiration and conserve blood. Ajit Rao, MD, a vascular surgeon with The Mount Sinai Hospital, performed the historic procedure.
FDA approves new nasal spray for patients with abnormal heart rhythms
Milestone Pharmaceuticals will be selling etripamil under the brand name Cardamyst. It is expected to hit the U.S. market in early 2026.
Philips to acquire AI-enabled intravascular imaging specialists SpectraWAVE
Massachusetts-based SpectraWAVE has gained considerable momentum in recent years, planting its flag in some of cardiology’s biggest trends. The company was co-founded by cardiologists and has already secured multiple FDA clearances.

money maze benjamin franklin reimbursement medicare

Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals.

Concomitant ablation surgery during heart operations boosts long-term survival

Treating AFib with surgical ablation during mitral valve surgery and other common heart operations can help patients live longer, a new meta-analysis confirmed.

The late-breaking U.S. multicenter admIRE clinical trial at the Heart Rhythm Society 2024 meeting, showed positive data on the long-term safety and effectiveness of the the Biosense Webster Varipulse pulsed field ablation (PFA) system in patients with paroxysmal atrial fibrillation. #HRS #HRS2024 #PFA

Johnson & Johnson MedTech gains FDA approval for Varipulse PFA system

Johnson & Johnson is now the third company with an FDA-approved PFA system in its portfolio, joining Medtronic and Boston Scientific. Varipulse previously gained CE mark approval in February.

The Abbott Esprit BTK everolimus-eluting biosorbable scaffold system for below the knee peripheral artery disease on display at TCT 2024. Photo by Dave FornellTCTn 2024 DF

Bioresorbable BTK stent superior to ballon angioplasty at 2 years

Late-breaking data from the LIFE-BTK clinical trial showed that the Esprit BTK bioresorbable scaffold system offered better two-year outcomes than balloon angioplasty in severe peripheral artery disease (PAD) below the knee.

Boston Scientific agrees to acquire AFib ablation company

Boston Scientific has scooped up Cortex, a healthcare technology company launched by the venture capital firm Ajax Health in 2023, in a move that will expand its EP offerings.

‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

HeartLung Technologies, a Houston-based artificial intelligence (AI) company, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for new software that assesses chest CT scans for signs of coronary artery disease (CAD) and other potentially fatal heart conditions. The newly cleared offering, AutoChamber, was designed with opportunistic heart evaluations in mind.

FDA clears AI tool that flags signs of heart disease in chest CT scans

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer.

The entrance to the AHA expo and technology floor. #AHA22

American Heart Association announces late-breaking research for Scientific Sessions 2024

The three-day conference begins Saturday, Nov. 16, in Chicago. Topics will include AI, heart failure, patient management and much more.

Cardiac Imaging

Societies must adapt to the rise of multimodality cardiac imaging

Women are more likely to have severe aortic stenosis missed on echocardiography results

New Medtronic thrombectomy system used commercially for first time

FDA approves new nasal spray for patients with abnormal heart rhythms

Philips to acquire AI-enabled intravascular imaging specialists SpectraWAVE